Self-enforcing Feedback Activation between Bcl6 and Pre-b Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia Self-enforcing Feedback Activation between Bcl6 and Pre-b Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia Figure 1. Expressi
A. Deucher,Markus Mü,Zhengshan Chen,S. Kornblau,B. Druker,E. Park,Sarah Thompson,Dorian H Latocha,Janet J Bijl,E. Ballabio,J. Tyner,Kyle Lenz,Dirk Baumjohann,Jaewoong Lee,B. H. Ye,H. Geng,Natalya A. Goloviznina,S. Hunger,Gang Xiao,S. Kweon,Ari Melnick,Bill H. Chang,Robert G. Roeder,S. Shojaee,Thomas A. Milne,Jianya Huan,R. Nahar,M. Loh,Wei-Yi Chen,Zhongxia Qi,L. Chan,Jan A Burger,Jingwei Yu,P. Kurre,K. Ansel,Markus Mü Schen,Chuanxin Huang,E. Paietta,C. Hurtz
Abstract:Graphical Abstract Highlights d ALL can be divided into two distinct subtypes based on pre-BCR function d Pre-BCR-induced activation of BCL6 further increased pre-BCR signaling output d Pre-BCR inhibitors reduced BCL6 levels and selectively killed pre-BCR + ALL cells d BCL6 represents a biomarker to identify patients with pre-BCR + ALL In Brief Geng et al. report the identification of a subset of human acute lymphoblastic leukemia (ALL) cases that critically depends on tonic pre-BCR signaling and is selectively sensitive to small molecule inhibitors of SYK and SRC tyrosine kinases downstream of the pre-BCR. SUMMARY Studying 830 pre-B ALL cases from four clinical trials, we found that human ALL can be divided into two fundamentally distinct subtypes based on pre-BCR function. While absent in the majority of ALL cases, tonic pre-BCR signaling was found in 112 cases (13.5%). In these cases, tonic pre-BCR signaling induced activation of BCL6, which in turn increased pre-BCR signaling output at the transcriptional level. Interestingly, inhibition of pre-BCR-related tyrosine kinases reduced constitutive BCL6 expression and selectively killed patient-derived pre-BCR + ALL cells. These findings identify a genetically and phenotypically distinct subset of human ALL that critically depends on tonic pre-BCR signaling. In vivo treatment studies suggested that pre-BCR tyrosine kinase inhibitors are useful for the treatment of patients with pre-BCR + ALL. Significance Recent work successfully introduced BCR signaling inhibitors into patient care for various subtypes of mature B cell lym-phoma, for example, Ibrutinib (BTK) and Idelalisib (PI3Kd), for germinal center-derived B cell lymphoma. However, it is not known whether pre-BCR signaling represents a therapeutic target in pre-B ALL. Here we report the identification of a subset of human ALL cases that critically depends on tonic pre-BCR signaling and is selectively sensitive to small molecule inhib-itors of SYK and SRC tyrosine kinases downstream of the pre-BCR. (A) Flow cytometry staining for cell cytoplasmic mHC. (B) Cell surface expression of the surrogate light-chain components l5 (IGLL1) and VpreB. (C) Ca 2+ mobilization in response to pre-BCR engagement using mHC-specific antibodies in different subtypes of ALL cases.
Medicine